Digital genome is an emerging technology in DNA sequencing, which allows sequencing and digitization of the human genome in minutes and at a cost of only a few hundred dollars. This is remarkably more efficient than the first sequencing of the 3.2 billion base pairs of DNA that make up the human genome, which took years to fully sequence and cost millions of dollars. It is a simpler way to gather information concerning chronic diseases and utilized by experts to get a nearer look of genetic disorders.
The global digital genome market is estimated to be valued at US$ 7,594.8 million in 2018, and is expected to witness a CAGR of 10.9% during the forecast period (2018-2026).
Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/136
Technological advancements in the field of digital genomes and increasing awareness about the use of genomes for diagnosis of various diseases, such as Attention Deficit Hyperactivity Disorder (ADHD), diabetes, and cancer, is expected to propel the growth of the global digital genome market over the forecast period. For instance, in February 2018, the National Human Genome Research Institute (NHGRI) announced the launch of new round of strategic planning that will establish a 2020 vision for genomics research to accelerate both medical and scientific breakthroughs. Moreover, NHGRI will identify paradigm-shifting areas of genomics to expand the field into new frontiers and enable novel applications to human health and disease.
Moreover, integration of advanced technologies, such as Machine Learning (ML) and Artificial Intelligence (AI) is expected to augment the growth of the global digital genome market. These technologies are being used to address various problems facing genomics, such as positioned nucleosomes, enhancers, identifying splice sites, and annotating genomic sequence elements, among others. For instance, Congenica’s clinical genomics analysis platform, named Sapientia, uses algorithms to annotate and priorities variants from whole-exome sequencing to assist in the diagnosis of rare diseases.
In 2017, Google announced the launch of technology to map human genome sequences called DeepVariant AI. It is a deep learning technology to reconstruct the true genome sequence from HTS sequencer data with significantly greater accuracy than previous classical methods.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/136
In February 2018, a national consortium of industry and academic collaborators announced the launch of the Canadian Genomics Cloud, an integrated software platform to manage, analyze, and share genome sequence and clinical data.
Furthermore, increasing adoption of personalized medicine is expected to augment the growth of the global digital genome market during the forecast period. Increasing prevalence of cancer, diabetes, and ADHD across the world is expected to aid in the growth of the market. According to the World Health Organization (WHO), cancer is a leading cause of death across the globe, accounting for nearly 14 million deaths in 2012. Moreover, WHO suggests that around 30 to 50% deaths caused due to cancer can be prevented by adequate treatment in early stages.
By Product Type:
- Sequencer & Analyzers
- Reagents & Kits and Sequencing & Analysis Software
- Clinical (Reproductive Health, Oncology, and Others)
- Drug Discovery and Development and Other Applications
By End User:
- Diagnostic Centers
- Research Institutes
- Biotechnology and Pharmaceutical Companies
- North America
- Latin America
- Asia Pacific
- Middle East and Africa
North America is expected to witness robust growth in the global digital genome market, owing to the increasing prevalence cancer, increasing awareness among people about the benefits of personalized medicines, and presence of key players in this region. Major players are focusing on launching novel products and gaining regulatory approvals.
Asia Pacific is expected to witness robust growth in the global digital genome market, owing to the increasing adoption of personalized medicine and increasing prevalence of diabetes and cancer in this region. For instance, in September 2018, Congenica announced it has entered into an agreement with a new strategic partner Digital China Health Technologies Cooperation Limited (DCHealth), further extending Congenica’s commitment to the Chinese market.
𝗦𝗮𝗹𝗲 𝗜𝘀 𝗟𝗶𝘃𝗲!
𝗕𝘂𝘆 𝗡𝗼𝘄 𝗧𝗼 𝗚𝗲𝘁 𝗙𝗹𝗮𝘁 𝟯𝟬 % 𝗢𝗳𝗳
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/136
Major players active in the global digital genome market are
- Ancestry.com LLC,
- Google LLC,
- Desktop Genetics Ltd.,
- Deep Genomics,
- Amazon.com, Inc.,
- Nanostring Technologies,
- Thermo Fisher Scientific Inc.,
- Pacific Biosciences of California, Inc.,
- PerkinElmer, Inc.,
- Illumina, Inc.,
- IBM Corporation, and
- Oxford Nanopore Technologies Limited, among others.
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027